Medication use was higher in the DKD group for most therapies: aspirin (9.8% vs. 3.8%), dual antiplatelet therapy (12.0% vs. 6.4%), statins (21.8% vs. 13.7%), sodium-glucose cotransporter-2 (SGLT2) inhibitors (53.4% vs. 33.4%), insulin (40.2% vs. 29.1%), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB; 36.8% vs. 12.1%). Here, SLC5A2 is linked to diabetic kidney disease.